SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Adial Pharmaceuticals Inc (ADIL) News

Follow Adial Pharmaceuticals Inc (ADIL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ADIL Asset equity Sector Markets 90 days 2 Last 4.95 Updated Oct 16, 2026, 11:00 AM UTC Open live news feed Open ADIL chart & news
L Adial Pharmaceuticals appoints David Rubenstein chief scientist David Rubenstein, M.D., Ph.D., was appointed chief scientist to advance AT177, a colon-targeted AhR agonist for ulcerative colitis. EQUITY | Oct 16, 2026, 11:00 AM UTC L Adial Pharmaceuticals announces Nasdaq inducement grant under Rule 5635(c)(4) Adial Pharmaceuticals (ADIL) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4). EQUITY | Aug 25, 2026, 08:05 PM UTC L Adial Pharmaceuticals reports 2026 Q2 financial results; business update Adial Pharmaceuticals (ADIL) reports 2026 second quarter financial results and provides a business update, according to TradeXchange Newsdesk. EARNINGS | Aug 17, 2026, 11:00 AM UTC M ADIL Initiated Buy Alliance Global Partners initiates ADIL buy EQUITY | Aug 03, 2026, 11:48 AM UTC L ADIL: Files SC 13G ADIL files SC 13G EQUITY | Jun 24, 2026, 02:36 PM UTC